AstraZeneca Unit Gets Partial Win in Soliris Drug Monopoly Case

A subsidiary of AstraZeneca Plc partly won its motion to dismiss a case accusing the pharmaceutical company of cornering the market for a blood disorder drug, after a federal judge tossed federal monopolization claims Friday but allowed allegations of sham litigation to proceed.

Judge Brian E. Murphy of the US District Court for the District of Massachusetts dismissed health insurer plaintiff EmblemHealth Inc.'s claims under Section 2 of the Sherman Act, which prohibits attempts to monopolize, and analogous state law claims.

But he said EmblemHealth “sufficiently pled facts” to suggest Alexion Pharmaceuticals Inc. knowingly obtained patents “through material misrepresentations and ...